Residual cancer burden (RCB) index was calculated using the web-based calculator (available on internet),25 by considering dimensions of the primary tumour, tumour bed cellularity and axillary nodal burden.8 RCB is composed of four categories: RCB‐0 (complete pathologic response = pCR), RCB...
Residual cancer burden NAC: Neoadjuvant chemotherapy RFS: Replase-free survival pCR: Pathologic complete response TNBC: Triple-negative breast cancer AUC: Area under curve BCS: Breast-conserving surgery CSCO: Chinese Society of Clinical Oncology ER: Estrogen receptor PR: Progesterone recepto...
This should separately describe whether there was residual invasive cancer in the breast, in situ cancer in the breast, and the pathologic status of the regional lymph nodes. Residual Cancer Burden as the preferred method for more detailed quantification of residual disease. The report should ...
Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) varies between 30 and 40% approximately. To provide further insight into the prediction of pCR, we evaluated the role of an epigenetic methy
This study aimed to validate the Clinical Treatment Score post-5 years (CTS5)-based risk stratification in a cohort comprising pre- and postmenopausal patients with estrogen receptor (ER)–positive breast cancer. We investigated the clinicopathologi
Neoadjuvant systemic therapy is being used increasingly in the treatment of early-stage breast cancer. Response, in the form of pathological complete response, is a validated and evaluable surrogate end point of survival after neoadjuvant therapy. Thus,
The residual cancer burden (RCB) calculator provides a standardized approach to assess the extent of residual invasive disease in the tumor bed and axillary lymph nodes after neoadjuvant therapy. Scores calculated using this tool were shown to be predictive of relapse-free survival at 10 years, and...
Consistently with its well-known prognostic role, HR status has been included in the AJCC BC staging system [17,18]. 3.7. Residual Cancer Burden 3.7.1. Consensus Statements Residual cancer burden (RCB) after neoadjuvant treatment is a feature correlated to the risk of relapse in surgically rese...
Axillary Staging in Ductal Carcinoma in Situ with Microinvasion: A Meta-Analysis. Surg. Oncol. 2021, 37, 101557. [Google Scholar] [CrossRef] [PubMed] Sopik, V.; Sun, P.; Narod, S.A. Impact of Microinvasion on Breast Cancer Mortality in Women with Ductal Carcinoma in Situ. Breast ...
Neoadjuvant systemic therapy has now become the standard in early breast cancer management. Chemotherapy in combination with trastuzumab +/− pertuzumab targeted therapy can improve the rates of pathologic complete response (pCR) in patients with HER2-positive breast cancer. Achieving a pCR is consider...